We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

Celcuity Inc. (NASDAQ:CELC) saw its stock soar by more than 100% on Monday following the release of groundbreaking Phase 3 ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant ...

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced ...

Investing.com -- Celcuity Inc. (NASDAQ: CELC) stock surged over 100% following the announcement of positive Phase 3 trial results for its breast cancer drug gedatolisib, which showed unprecedented ...

Celcuity said its Phase 3 clinical trial evaluating gedatolisib resulted in positive topline results. The clinical-stage biotechnology company's trial evaluated gedatolisib plus fulvestrant with and ...

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...